Form 8-K - Current report:
SEC Accession No. 0001764013-25-000024
Filing Date
2025-02-06
Accepted
2025-02-06 06:37:53
Documents
14
Period of Report
2025-02-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20250206.htm   iXBRL 8-K 27325
2 EX-99.1 exhibit9912025206.htm EX-99.1 86531
  Complete submission text file 0001764013-25-000024.txt   247196

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20250206.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20250206_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20250206_pre.xml EX-101.PRE 12506
16 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20250206_htm.xml XML 2712
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 25595364
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)